Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 06, 2025 07:00 ET | Source: Noema Pharma AG

Noema Pharma Announces Phase 2a Study Results with Cendifensine in Women with Vasomotor Symptoms (Hot Flashes) Due to Menopause

BASEL, Switzerland and BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Noema Pharma AG today announced positive topline results from a Phase 2a, open-label study evaluating cendifensine in menopausal...
January 08, 2025 08:00 ET | Source: Noema Pharma AG

Noema Pharma Appoints Michael Samar as Chief Financial Officer

BASEL, Switzerland, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced the appointment of...
December 18, 2024 08:00 ET | Source: Noema Pharma AG

Noema Pharma Appoints Volker Knappertz, M.D., as Executive Vice President of Research & Development

BASEL, Switzerland, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced the appointment of...
October 30, 2024 08:00 ET | Source: Noema Pharma AG

Noema Pharma Announces First Patients Dosed in Phase 2b Study with Gemlapodect (NOE-105), a First-In-Class Investigational Therapy for Tourette Syndrome

BASEL, Switzerland, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Noema Pharma AG, a clinical-stage neuroscience-based company, today announced the first patients have been dosed in a global Phase 2b study...
October 17, 2024 08:00 ET | Source: Noema Pharma AG

Noema Pharma Announces NOE-105 (gemlapodect) Phase 2a Study in Tourette Syndrome met Primary and all Key Secondary Endpoints

– Topline results from Phase 2a study – Nearly 60% of all patients treated with gemlapodect and 88% of patients completing the study at the target clinical dose range were responders based on the...
August 13, 2024 08:00 ET | Source: Noema Pharma AG

Noema Pharma Announces Completion of Enrollment for GALENE Phase 2B Trial Evaluating NOE-101, a First-in-Class mGluR5 NAM, for Seizure Control in Tuberous Sclerosis Complex

-- Top-line results from Phase 2B study expected in first quarter of 2025 -- BASEL, Switzerland, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Noema Pharma AG, a clinical-stage biotech company targeting...
May 22, 2024 08:00 ET | Source: Noema Pharma AG

Noema Pharma Announces First Patient Dosed in Phase 2a Study of NOE-115, a First-In-Class Investigational Therapy for the Treatment of Vasomotor Symptoms and Additional Symptoms Associated with Menopause

BASEL, Switzerland, May 22, 2024 (GLOBE NEWSWIRE) -- Noema Pharma AG, a clinical-stage biotech company targeting debilitating neuroscience-based disorders, today announced the first patient has been...
January 03, 2024 08:00 ET | Source: Noema Pharma AG

Noema Pharma to Present at Two Upcoming Conferences

BASEL, Switzerland, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced that members of...
November 15, 2023 08:00 ET | Source: Noema Pharma AG

Noema Pharma Appoints Robert Lasser, M.D., as Chief Medical Officer

BASEL, Switzerland, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced Robert Lasser,...
June 21, 2023 07:00 ET | Source: Noema Pharma AG

Noema Pharma Appoints Ilise Lombardo, M.D., as Chief Executive Officer

BASEL, Switzerland, June 21, 2023 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced the appointment of...